MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ejim.2026.107219

Медицинская библиотека · European journal of internal medicine · 2026

Statins are associated with decreased risk of disease progression and death in non-cirrhotic patients with primary biliary cholangitis.

Rigopoulou Eirini I, Lygoura Vasiliki, Papantoniou Konstantinos, Gabeta Stella, Samakidou Anna, Sveroni Dafni, Giannoulis George, Gatselis Nikolaos, Zachou Kalliopi, Triantos Christos, Dalekos George N

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND/AIMS: We evaluated whether statins in non-cirrhotic patients with primary biliary cholangitis (PBC) might influence disease progression, including cirrhosis development, hepatic decompensation, all-cause mortality, liver-related death (LRD) and non-liver-related death (NLRD), as such data are missing.

MATERIALS AND

METHODS

We retrospectively analyzed prospectively collected data in 507 non-cirrhotic PBC patients (445 females, age: 53 (16) years, follow-up: 85 (130) months) including 232 that received statins due to increased cardiovascular risk and 275 that had no treatment with statins during the follow-up.

RESULTS

There were no significant differences between the two groups in baseline demographic, clinical and laboratory characteristics except for higher cholesterol, LDL and triglyceride levels and higher frequency of MASLD/MASH in statin users. No differences in treatment response to UDCA (GLOBE score, Paris II) were noted between the groups. Statin users had lower rate of cirrhosis development (3.4% vs. 8%; p=0.03), hepatic decompensation (0.4% vs 4.7%; p=0.003), lower all-cause mortality (3.9% vs. 16.4%; p<0.001), LRD (0.4% vs. 5.1%; p=0.002) and NLRD (3.4% vs. 11.3%; p,0.001) compared to no-statin users. A time-dependent Cox regression analysis revealed significantly higher cirrhosis-free survival (HR=0.139; 95%CI 0.041-0.467, p=0.001) and significantly lower risk of all-cause mortality (HR=0.318; 95%CI 0.153-0.661, p=0.002) and LRDs (HR=0.076; 95%CI 0.010-0.584, p=0.013), while no significant difference was found regarding NLRDs (HR=0.499; 95%CI 0.224-1.111, p=0.089) in statin users compared to non-users.

CONCLUSIONS

Statins seem to independently associate with higher cirrhosis-free survival and lower overall and liver-related mortality in non-cirrhotic patients with PBC. Larger prospective studies are needed to confirm our novel data.

Для цитирования: Rigopoulou Eirini I, Lygoura Vasiliki, Papantoniou Konstantinos, Gabeta Stella, Samakidou Anna, Sveroni Dafni, Giannoulis George, Gatselis Nikolaos, Zachou Kalliopi, Triantos Christos, Dalekos George N. Statins are associated with decreased risk of disease progression and death in non-cirrhotic patients with primary biliary cholangitis.. European journal of internal medicine. 2026. DOI: 10.1016/j.ejim.2026.107219.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.